Driving the degradation of oncofusion proteins for targeted cancer therapy
{{output}}
Oncofusion proteins drive the development of about 16.5% of human cancers, functioning as the unique pathogenic factor in some cancers. The targeting of oncofusion proteins is an attractive strategy to treat malignant tumors. Recently, triggering the degradati... ...
